Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether KAI-9803 is safe and effective in reducing
infarct size in subjects with ST elevation myocardial infarction (heart attack) undergoing a
percutaneous coronary intervention (PCI). A select number of sites will also participate in a
substudy where eligible patients will undergo an additional procedure;cardiac magnetic
resonance imaging.
Phase:
Phase 2
Details
Lead Sponsor:
KAI Pharmaceuticals
Collaborators:
Bristol-Myers Squibb Duke University The Cleveland Clinic